KRYS
Krystal Biotech, Inc.
$311.50
-2.70%
2026-10-23
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Key Fundamentals
P/E Ratio
43.28
Forward P/E
37.11
EPS (TTM)
$7.99
ROE
20.1%
Revenue Growth (YoY)
24.1%
Profit Margin
54.8%
Debt/Equity
0.65
Price/Book
7.53
Beta
0.54
Market Cap
$10.24B
Avg Volume (10D)
318K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$373.31
60D Low
$297.02
Avg Volume
279K
Latest Close
$311.50
Get breakout alerts for KRYS
Sign up for Breakout Scanner to receive daily notifications when KRYS triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Krystal Biotech, Inc. (KRYS) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors KRYS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. KRYS operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.